Moomoo AI 已提取核心訊息
On February 25, 2024, iBio Inc, a Delaware-incorporated biopharmaceutical company, announced the completion of a significant asset sale to Otsuka Pharmaceutical Co., Ltd. The deal involved the sale of iBio's PD-1 agonist assets, which are intellectual property rights related to the company's early-stage programmed cell death protein 1 agonist program. The transaction, which closed on the same day, included an upfront payment of $1 million to iBio, with additional potential contingent payments totaling up to $52.5 million based on the achievement of certain clinical development and commercial milestones. This sale is part of iBio's strategic focus on its proprietary immuno-oncology pipeline and AI-based drug discovery platform. The PD-1 agonist program was initially acquired by iBio from RubrYc Therapeutics...Show More
On February 25, 2024, iBio Inc, a Delaware-incorporated biopharmaceutical company, announced the completion of a significant asset sale to Otsuka Pharmaceutical Co., Ltd. The deal involved the sale of iBio's PD-1 agonist assets, which are intellectual property rights related to the company's early-stage programmed cell death protein 1 agonist program. The transaction, which closed on the same day, included an upfront payment of $1 million to iBio, with additional potential contingent payments totaling up to $52.5 million based on the achievement of certain clinical development and commercial milestones. This sale is part of iBio's strategic focus on its proprietary immuno-oncology pipeline and AI-based drug discovery platform. The PD-1 agonist program was initially acquired by iBio from RubrYc Therapeutics on September 19, 2022, and the sale to Otsuka represents a significant potential source of non-dilutive capital for iBio. The company's press release on February 26, 2024, emphasized the importance of the transaction for both iBio and Otsuka, with iBio's CEO highlighting the validation of their technology stack and the focus on developing their immuno-oncology candidates.
2024年2月25日，特拉華州註冊的生物製藥公司iBio Inc宣佈完成對大冢製藥有限公司的重大資產出售，該交易涉及出售iBio的PD-1激動劑資產，這些資產是與該公司早期程序性細胞死亡蛋白1激動劑計劃相關的知識產權。該交易於當天完成，包括向iBio預付100萬美元，以及根據某些臨床開發和商業里程碑的實現情況，額外潛在的或有付款總額高達5,250萬美元。此次出售是iBio在其專有的免疫腫瘤學產品線和基於人工智能的藥物發現平台上的戰略重點的一部分。PD-1激動劑項目最初由iBio於2022年9月19日從RubryC Therapeutics手中收購，向大冢出售是iBio非稀釋資本的重要潛在來源。該公司於2024年2月26日發佈的新聞稿強調了該交易對iBio和大冢的重要性，iBio的首席執行官強調了其技術堆棧的驗證以及對開發免疫腫瘤學候選藥物的關注。
2024年2月25日，特拉華州註冊的生物製藥公司iBio Inc宣佈完成對大冢製藥有限公司的重大資產出售，該交易涉及出售iBio的PD-1激動劑資產，這些資產是與該公司早期程序性細胞死亡蛋白1激動劑計劃相關的知識產權。該交易於當天完成，包括向iBio預付100萬美元，以及根據某些臨床開發和商業里程碑的實現情況，額外潛在的或有付款總額高達5,250萬美元。此次出售是iBio在其專有的免疫腫瘤學產品線和基於人工智能的藥物發現平台上的戰略重點的一部分。PD-1激動劑項目最初由iBio於2022年9月19日從RubryC Therapeutics手中收購，向大冢出售是iBio非稀釋資本的重要潛在來源。該公司於2024年2月26日發佈的新聞稿強調了該交易對iBio和大冢的重要性，iBio的首席執行官強調了其技術堆棧的驗證以及對開發免疫腫瘤學候選藥物的關注。
有用
沒用
